MEDICINE FOUNDRY

Serial Number 98780309
688

Registration Progress

Application Filed
Oct 1, 2024
Under Examination
May 6, 2025
Approved for Publication
Mar 11, 2025
Published for Opposition
Mar 11, 2025
Registered

Basic Information

Serial Number
98780309
Deadline
November 6, 2025
Description
Statement of Use or 1st Extension Due
Filing Date
October 1, 2024
Published for Opposition
March 11, 2025
Drawing Code
4

Status Summary

Current Status
Active
Status Code
688
Status Date
May 6, 2025
Application
Pending
Classes
040 042

Rights Holder

Eli Lilly and Company

03
Address
Lilly Corporate Center
Indianapolis, IN 46285

Ownership History

Eli Lilly and Company

Original Applicant
03
Indianapolis, IN

Eli Lilly and Company

Owner at Publication
03
Indianapolis, IN

Legal Representation

Attorney
Bruce W. Longbottom
USPTO Deadlines 3 active 2 overdue
Deadline Type Event Code Deadline Date Days Until Priority Extension Available
EXAMINER AMENDMENT
Examiner's Amendment Completed
CNEA Feb 28, 2025 129 days overdue Low No
OPPOSITION
Notice of Publication
NPUB Apr 10, 2025 88 days overdue Medium Until May 10, 2025
ITU SOU
Notice of Allowance Mailed - SOU Required
NOAM Nov 06, 2025 122 days High Until May 06, 2026
Next deadline: Notice of Allowance Mailed - SOU Required on November 06, 2025 (122 days)

Application History

12 events
Date Code Type Description
May 6, 2025 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 11, 2025 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 11, 2025 PUBO A PUBLISHED FOR OPPOSITION
Mar 5, 2025 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 13, 2025 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 13, 2025 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 13, 2025 GNEA F EXAMINERS AMENDMENT E-MAILED
Feb 13, 2025 XAEC I EXAMINER'S AMENDMENT ENTERED
Feb 13, 2025 CNEA R EXAMINERS AMENDMENT -WRITTEN
Feb 5, 2025 DOCK D ASSIGNED TO EXAMINER
Oct 1, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 1, 2024 NWAP I NEW APPLICATION ENTERED

Detailed Classifications

Class 040
Custom manufacturing of pharmaceuticals and clinical trial materials
Class 042
Pharmaceutical products development; Product research; Research and development in the pharmaceutical and biotechnology fields

Classification

International Classes
040 042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"MEDICINE"